MX367671B - Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis. - Google Patents

Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis.

Info

Publication number
MX367671B
MX367671B MX2014009464A MX2014009464A MX367671B MX 367671 B MX367671 B MX 367671B MX 2014009464 A MX2014009464 A MX 2014009464A MX 2014009464 A MX2014009464 A MX 2014009464A MX 367671 B MX367671 B MX 367671B
Authority
MX
Mexico
Prior art keywords
enuresis
pharmaceutical composition
urinary incontinence
treating urinary
composition
Prior art date
Application number
MX2014009464A
Other languages
English (en)
Other versions
MX2014009464A (es
Inventor
Carlos Llobregat Agusti Juan
Original Assignee
Laboratec S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratec S L filed Critical Laboratec S L
Publication of MX2014009464A publication Critical patent/MX2014009464A/es
Publication of MX367671B publication Critical patent/MX367671B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736Prunus, e.g. plum, cherry, peach, apricot or almond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para tratamiento de incontinencia urinaria y/o enuresis que comprende al menos una mezcla de flavonoides entre el 0,5% - 20% en peso, de taninos condensados o proantocianidinas entre el 2% - 20% en peso y de ácido Gamma-aminobutírico (GABA) entre el 0,3% - 60% en peso, sobre el total de la composición. Dicha composición adicionalmente comprende al menos 50% de un extracto de Humulus lupulus. La presente invención también se refiere al uso de dicha composición para la obtención de un medicamento para tratar la incontinencia y/o enuresis, particularmente la enuresis en niños, así como en adultos o ancianos que tienen pérdidas de orina como la incontinencia de estrés o de urgencia.
MX2014009464A 2012-02-15 2013-01-22 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis. MX367671B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201230242A ES2423254B1 (es) 2012-02-15 2012-02-15 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis
PCT/ES2013/070022 WO2013121061A1 (es) 2012-02-15 2013-01-22 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis

Publications (2)

Publication Number Publication Date
MX2014009464A MX2014009464A (es) 2014-11-12
MX367671B true MX367671B (es) 2019-08-30

Family

ID=48983578

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009464A MX367671B (es) 2012-02-15 2013-01-22 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis.

Country Status (20)

Country Link
US (1) US9272011B2 (es)
EP (1) EP2815755A4 (es)
JP (1) JP6203761B2 (es)
KR (1) KR20140127874A (es)
CN (1) CN104254338B (es)
AU (1) AU2013220284A1 (es)
BR (1) BR112014020154A8 (es)
CA (1) CA2864426A1 (es)
CL (1) CL2014002128A1 (es)
CO (1) CO7141408A2 (es)
CR (1) CR20140419A (es)
EA (1) EA028184B1 (es)
ES (1) ES2423254B1 (es)
IL (1) IL233978A0 (es)
MA (1) MA37324A1 (es)
MX (1) MX367671B (es)
PE (1) PE20142324A1 (es)
PH (1) PH12014501823A1 (es)
WO (1) WO2013121061A1 (es)
ZA (1) ZA201406668B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110339316B (zh) * 2019-08-09 2021-09-21 河南中医药大学 一种治疗中风后尿失禁的中药
CN116036153B (zh) * 2023-02-22 2023-09-26 深圳市儿童医院 啤酒花提取物在制备用于治疗或者预防抑郁症、抑郁症并发症、焦虑症的产品中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9137091A (en) 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
RU94046105A (ru) 1992-05-20 1997-06-20 Нортвестерн Юниверсити (Us) АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JP2002541198A (ja) * 1999-04-08 2002-12-03 ワーナー−ランバート・カンパニー 失禁の治療法
FR2823672B1 (fr) * 2001-04-23 2004-03-12 Berkem Sa Extraits de houblon et leur utilisation dans la preparation d'un medicament ayant des proprietes oestrogenes
JP2003088335A (ja) * 2001-09-14 2003-03-25 Pharmafoods Kenkyusho:Kk 排尿機能改善用食品組成物及びそれを含有する飲食品
GB0306568D0 (en) * 2003-03-21 2003-04-30 Unilever Plc Compositions of natural products and use thereof
NZ526350A (en) * 2003-06-09 2004-10-29 A Anti-aging compositions comprising an amino acid, vitamin B complex, metal salt and an amino alcohol
CN1867327A (zh) * 2003-09-11 2006-11-22 什诺波特有限公司 使用gaba类似物的前药治疗和/或预防尿失禁
NZ546138A (en) * 2003-10-09 2009-12-24 Pacific Arrow Ltd Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US20070116839A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith
EP1889612A3 (en) * 2006-07-24 2008-03-19 Jan Kees Piet Bruinstroop Method for controlling micturition
US20090180999A1 (en) * 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition

Also Published As

Publication number Publication date
KR20140127874A (ko) 2014-11-04
US20150044308A1 (en) 2015-02-12
IL233978A0 (en) 2014-09-30
CR20140419A (es) 2014-11-28
US9272011B2 (en) 2016-03-01
WO2013121061A1 (es) 2013-08-22
CA2864426A1 (en) 2013-08-22
BR112014020154A8 (pt) 2017-07-11
PH12014501823A1 (en) 2014-11-24
AU2013220284A1 (en) 2014-09-25
PE20142324A1 (es) 2015-01-16
MA37324A1 (fr) 2016-03-31
JP2015507002A (ja) 2015-03-05
CL2014002128A1 (es) 2015-03-13
CN104254338A (zh) 2014-12-31
CN104254338B (zh) 2019-05-31
ZA201406668B (en) 2016-05-25
EA201491437A1 (ru) 2015-06-30
BR112014020154A2 (es) 2017-06-20
ES2423254A1 (es) 2013-09-18
CO7141408A2 (es) 2014-12-12
EA028184B1 (ru) 2017-10-31
EP2815755A1 (en) 2014-12-24
JP6203761B2 (ja) 2017-09-27
EP2815755A4 (en) 2015-08-05
MX2014009464A (es) 2014-11-12
ES2423254B1 (es) 2014-03-26

Similar Documents

Publication Publication Date Title
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
WO2011000566A3 (en) Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
UY32497A (es) "2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso"
BR112019024747A2 (pt) formulações de dose fixa
WO2010089128A3 (en) Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
ATE411033T1 (de) Formulierung zur behandlung von fettleibigkeit und assoziiertem stoffwechselsyndrom
CL2012001971A1 (es) Compuestos derivados de 1-piperazinil-3-piridin-carboxilato, como bloqueadores de los canales de sodio dependientes de voltaje; composicion farmaceutica; y su uso para el tratamiento de enfermedades respiratorias o del tracto respiratorio tal como asma, epoc, tos, silicosis, entre otras.
BR112014031914A2 (pt) cápsula de estradiol solúvel para inserção vaginal
WO2014049447A3 (en) A whole, leech saliva extract
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".
CO7101247A2 (es) Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
BR112012013199A8 (pt) Composto, composição farmacêutica, e , uso de um composto
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
UY32650A (es) Medicamento para la administración oral que contiene al menos un esterógeno y/o al menos un gestágeno y al menos una cepa de bacterias probióticas
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
PH12014501823A1 (en) Pharmaceutical composition for treating urinary incontinence and enuresis
WO2011055931A3 (ko) 인플루엔자 바이러스 유래 질병의 예방 또는 치료용 조성물
MX2010001403A (es) Composicion topica que contiene una combinacion de mupirocina y beclometasona.
CL2011002893A1 (es) Peptido derivado del factor viii; composicion que lo comprende; uso para aumentar la tolerancia a factor viii en individuos que padecen o estan en riesgo de padecer hemofilia a o hemofilia adquirida.
BR112014016804A8 (pt) composições, métodos de uso e métodos de tratamento
WO2012138911A3 (en) Conjugates of anti-hiv drugs and somatostatin analogs
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
WO2013090965A3 (de) Zusammensetzung enthaltend antikörper gegen gluten und gerbstoffe

Legal Events

Date Code Title Description
FG Grant or registration